Overview

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Status:
Recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
The study is designed to investigate the safety, tolerability and preliminary efficacy in combination with CN1 and CN401 in adult patients with relapsed/refractory lymphoid malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Curon Biopharmaceutical (Australia) Co Pty Ltd
Collaborator:
Novotech (Australia) Pty Limited